Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Inventory (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Change in Inventory for 6 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 640.97% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 32.92% increase, with the full-year FY2025 number at $3.4 million, up 32.92% from a year prior.
  • Change in Inventory was $3.4 million for Q4 2025 at GeneDx Holdings, up from -$1.3 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $9.8 million in Q1 2021 to a low of -$7.6 million in Q4 2022.
  • A 5-year average of $666000.0 and a median of $465500.0 in 2024 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 640.97% in 2025; the steepest drop was 379.25% in 2025.
  • GeneDx Holdings' Change in Inventory stood at $3.3 million in 2021, then crashed by 330.67% to -$7.6 million in 2022, then soared by 96.14% to -$293000.0 in 2023, then soared by 254.95% to $454000.0 in 2024, then skyrocketed by 640.97% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Change in Inventory are $3.4 million (Q4 2025), -$1.3 million (Q3 2025), and -$628000.0 (Q2 2025).